Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06769165

EMDR Treatment of Conditioned Nausea and Vomiting in Cancer Survivors

EMDR Treatment of Conditioned Nausea and Vomiting in Cancer Survivors - a Pilot Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
University Medical Center Groningen · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

To explore the effectiveness of EMDR therapy treatment in reducing symptoms of chemotherapy-induced conditioned nausea and vomiting in (former) patients with cancer.

Detailed description

Conditioned nausea and vomiting is a common side effect of anti-cancer treatment, and while strategies like antiemetics exist, their effectiveness is limited. Conditioned nausea and vomiting can possibly be addressed through Eye Movement Desensitization and Reprocessing (EMDR) therapy. EMDR therapy is a therapeutic intervention, proven to be effective in the treatment of post-traumatic stress disorder (PTSD), and promising in treating a range of other conditions. At the UMCG, EMDR therapy is used on a small scale to treat conditioned nausea with positive results, although more rigorous research is needed to fully establish its efficacy. This study aims to explore the effectiveness of EMDR therapy treatment in reducing symptoms of chemotherapy-induced conditioned nausea and vomiting in (former) patients with cancer.

Conditions

Interventions

TypeNameDescription
OTHEREMDR therapyIn this study, EMDR therapy will be performed by psychologists of the UMCG who are trained in EMDR therapy and who have experience with patients with somatic diseases. In the EMDR therapy protocol, the patient is guided through eight phases which incorporate dual focus of attention and alternating bilateral visual, auditory, and/or tactile stimulation (see supplement for protocol). The number of sessions varies per patient (1-3 sessions), depending on the desensitization of the conditioned stimuli. The sessions will last 60-90 minutes.

Timeline

Start date
2025-07-02
Primary completion
2026-08-01
Completion
2026-08-01
First posted
2025-01-10
Last updated
2025-12-11

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT06769165. Inclusion in this directory is not an endorsement.